NASDAQ: INKTMink Therapeutics Inc Stock
$9.74-0.54 (-5.25%)
Updated Mar 13, 2026
INKT Price
$9.74
Fair Value Price
-$0.09
Market Cap
$45.72M
52 Week Low
$6.34
52 Week High
$76.00
P/E
-3.17x
P/B
-3.38x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$12.36M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-2.11
Operating Cash Flow
-$6M
Beta
0.53
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
INKT Overview
MiNK Therapeutics Incorporated is developing allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company's product candidate, AGENT-797, is in Phase 1 clinical trials. Formerly known as AgenTus Therapeutics Inc., MiNK Therapeutics was incorporated in 2017 and is headquartered in New York, NY.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine INKT's potential to beat the market
- INKT doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
INKT
RankedUnranked of 469
RankedUnranked of 469
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $14.51 | A | |
| $32.13 | A | |
| $178.55 | A |
Be the first to know about important INKT news, forecast changes, insider trades & much more!
INKT News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how INKT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
INKT ($9.74) is overvalued by 10,926.25% relative to our estimate of its Fair Value price of -$0.09 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
INKT ($9.74) is not significantly undervalued (10,926.25%) relative to our estimate of its Fair Value price of -$0.09 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
INKT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more INKT due diligence checks available for Premium users.
Valuation
INKT fair value
Fair Value of INKT stock based on Discounted Cash Flow (DCF)
Price
$9.74
Fair Value
-$0.09
Undervalued by
10,926.25%
INKT ($9.74) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
INKT ($9.74) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
INKT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
INKT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.17x
Industry
29.31x
Market
31.82x
INKT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-3.38x
Industry
4.7x
INKT's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.9M
Profit Margin
0%
INKT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$15.0M
Liabilities
$28.5M
Debt to equity
-2.11
INKT's short-term assets ($14.53M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
INKT's long-term liabilities ($15.04M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
INKT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
INKT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$941.3k
Investing
$0.0
Financing
$13.5M
INKT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
INKT vs Biotech Stocks
Mink Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.